Harrow, Inc. announced its audited financial results for the fourth quarter and full year ended December 31, 2024. The company reported record fourth-quarter revenues of $66.831 million, marking an 84% increase year-over-year. Full-year 2024 revenues reached $199.614 million, a 53% increase over 2023.
For the fourth quarter, Harrow achieved a GAAP net income of $6.777 million, a significant improvement from a net loss of $(9.148) million in Q4 2023. Full-year 2024 GAAP net loss was $(17.481) million, an improvement from $(24.411) million in 2023. Adjusted EBITDA for Q4 2024 was $22.489 million, and for the full year, it was $40.327 million.
Mark L. Baum, CEO, highlighted the strong finish to a transformative year, driven by over 40% quarter-over-quarter growth in both IHEEZO unit demand and VEVYE prescriptions. The company reaffirmed its 2025 revenue guidance of 'more than $280 million,' representing an expected increase of over 40% in annual revenues compared to 2024.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.